Xcout IntelImmune Design
Immune Design Corp. is a clinical-stage immunotherapy company with offices in Seattle, Washington, and South San Francisco, California, specializing in novel drug discovery and treatment technologies.
Subscribe to see Immune Design’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Immune Design at a glance
Immune Design is a biotechnology company headquartered in United States. It has raised at least $99M across the 3 funding rounds on record. Its most recent funding round, Series C, raised $49M in October 2013. Xcout tracks 11 named people at Immune Design, including David Burkhart (Chief Executive Officer).
Immune Design leadership
- David BurkhartChief Executive Officer
- Ferdinand E. MassariChief Medical Officer
- Jay EvansChief Scientific & Strategy Officer
- Helene Bazin-LeeVP, Discovery
- Joseph SulovskiVP, Clinical Operations
- Kendal RyterVP, Manufacturing & Dev.
5 more named people on record for Immune Design, with roles, board committees and tenure — see the full roster →
Immune Design funding rounds
At least $99M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $49M | — | |
| Series A | $18M | — | |
| Series B | $32M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Immune Design competitors
A few of Immune Design's closest competitors — see the full list of competitors and alternatives →
Amphivena Therapeutics, Inc. is a privately held, clinical-stage biotechnology company based in South San Francisco, California. The company specializes in immuno-oncology, developing a platform of dual-function biologics and selective T cell engagers for the treatment of hematological conditions.
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.
NGM Biopharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on discovering and developing transformative therapeutics.
Sift Biosciences is a privately held biotechnology company founded in 2024 and headquartered in San Carlos, California. The company is focused on harnessing pre-existing hidden immunity.
Dualitas Therapeutics is a privately held biotechnology research company headquartered in South San Francisco, California, that utilizes its DualScreen Bispecific Discovery Engine for proximity engagers.
Get Immune Design's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Immune Design in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access